Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives
| EIGRDelisted Stock | USD 0.74 0.03 3.90% |
Slightly above 62% of Eiger Biopharmaceutica's investor base is looking to short. The analysis of current outlook of investing in Eiger Biopharmaceuticals suggests that many traders are alarmed regarding Eiger Biopharmaceutica's prospects. Eiger Biopharmaceutica's investing sentiment overview a quick insight into current market opportunities from investing in Eiger Biopharmaceuticals. Many technical investors use Eiger Biopharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Eiger |
Eiger BioPharmaceuticals files for Chapter 11 bankruptcy protection. Plans to sell Zokinvy to Sentynl Therapeutics or up to 26.0 million. Potential bidders can submit competing bids.
Read at benzinga.com
 |
Eiger Biopharmaceutica Fundamental Analysis
We analyze Eiger Biopharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eiger Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eiger Biopharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Eiger Biopharmaceutica is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Eiger Biopharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eiger Biopharmaceutica stock to make a market-neutral strategy. Peer analysis of Eiger Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Eiger Biopharmaceutica by comparing valuation metrics with similar companies.
Peers
Eiger Biopharmaceutica Related Equities
| XFOR | X4 Pharmaceuticals | 13.54 | ||||
| CNTB | Connect Biopharma | 7.89 | ||||
| APLT | Applied Therapeutics | 2.48 | ||||
| CHRS | Coherus BioSciences | 1.86 | ||||
| SPRO | Spero Therapeutics | 1.75 | ||||
| ABOS | Acumen Pharmaceuticals | 0.46 | ||||
| ETON | Eton Pharmaceuticals | 0.25 | ||||
| UNCY | Unicycive Therapeutics | 0.04 | ||||
| DAWN | Day One | 0.45 | ||||
| HOWL | Werewolf Therapeutics | 0.54 | ||||
| INZY | Inozyme Pharma | 0.67 | ||||
| NUVB | Nuvation Bio | 1.11 | ||||
| CING | Cingulate | 1.15 | ||||
| BOLT | Bolt Biotherapeutics | 2.37 | ||||
| ELDN | Eledon Pharmaceuticals | 3.11 | ||||
| TERN | Terns Pharmaceuticals | 3.18 | ||||
| LYRA | Lyra Therapeutics | 6.86 | ||||
| SPRB | Spruce Biosciences | 20.46 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| CEOs Directory Screen CEOs from public companies around the world |